EGFR和mTOR特异性标记与肿瘤治疗关系现状

摘要

Worldwide, tumor mortality rates remain high , and how to strengthen the oncotherpay and improve the life quality of the patients remains a concern and urgent problem .Molecular targeted therapy is a new-type treatment that has better specificity but less adverse effect .In current research,in a variety of tumors the application of molecular targeted therapy is increasing.Epidermal growth factor receptor and mammalian target of rapamycin,which have been widely used,showed their clinical value of application in tumor-targeted therapy in both independent and combined ways.%在全球范围内，肿瘤的致死率仍然居高不下，如何加强肿瘤治疗及改善患者的生存质量仍是目前关注的焦点和亟需解决的问题。分子靶向治疗是一种针对性较强、不良反应较小的新型治疗手段，目前在多种肿瘤治疗中对于应用分子靶向治疗的研究不断增多。表皮生长因子受体及哺乳动物雷帕霉素靶蛋白是目前应用较为广泛的两种生物标志物，在肿瘤靶向治疗过程中无论独立或联合应用均具有较高的临床价值。